Determination of synthetic pharmaceutical adulterants in herbal weight gain supplements sold in herb shops, Tehran, Iran

Niosha Saberi 1 · Maryam Akhgari 2 · Leila Bahmanabadi 2 · Elham Bazmi 2 · Zahra Mousavi 1

Received: 4 July 2018 / Accepted: 4 September 2018 / Published online: 21 September 2018
© Springer Nature Switzerland AG 2018

Abstract
Background Nowadays with the growing popularity of herbal remedies across the world, large sections of population rely on herbal drug practitioners for their primary care. Therefore there is a need to ensure about the safety of herbal drugs and to detect adulteration with undeclared active pharmaceutical ingredients. Herbal drugs are used as first-line drug therapy in some instances. Unfortunately even if there are claims as to be natural, undeclared active pharmaceutical ingredients have been detected in these supplements.

Objectives The purpose of the present study was to analyse herbal weight gain drugs collected from herb shops located in Tehran, Iran to detect hidden pharmaceutical ingredients using UHPLC and GC/MS instrumentations.

Methods Sixty herbal drugs advertised as weight gain supplements were gathered from herb shops Tehran province, Iran. All samples were analysed from analytical toxicology point of view to detect undeclared active pharmaceutical ingredients. Method was validated for quantitative analysis of cyproheptadine and dexamethasone.

Results Method validity parameters showed good results for quantitative analysis of pharmaceutical ingredients. Cyproheptadine, dexamethasone, sildenafil, tramadol, caffeine and acetaminophen were detected in herbal weight gain drugs. Analysed dosage forms contained cyproheptadine and dexamethasone in concentrations higher than therapeutic doses. Quantitative analysis of contaminated drugs showed that the content of pharmacologic ingredients were 0.2–67 and 5.5–10.1 mg/tablet or capsule for cyproheptadine and dexamethasone respectively.

Conclusions Despite natural supplements producers’ claim, herbal weight gain drugs were not natural at all. Undeclared active pharmaceutical ingredients can predispose patients to health problems and even life-threatening situations.

Keywords Herbal drugs · Adulteration · Weight gain · Analytical toxicology · Cyproheptadine · Dexamethasone

Introduction
In the last few years use of natural drugs especially those labeled as plant origin supplements is experiencing a considerable growth in Iran and some countries [1]. Since ancient times, herbal drugs had been used for many purposes, to maintain well-being or as medicines in many situations such as addiction treatment, sexual performance enhancing, bodybuilding, athletic performance enhancement and obesity treatment [2–7]. There is a need to evaluate herbal drugs and natural supplements to gain a proven degree of efficacy and safety in many countries [8, 9]. In spite of the need for registration and marketing authorization for all drugs before entering drug market in Iran under the supervision of Iran Food and Drug Administration (IFDA) [10], local herb shops do not obey this law and there is no control for the production and distribution of their hand-made products. Unfortunately hand-made herbal drugs are not screened from efficacy and safety perspectives and this issue doesn’t have priority for manufacturers due to high cost [8]. Counterfeit and substandard drugs constitute a global problem affecting health care systems in low and
middle-income countries and also industrialized world [11].
This problem is an interest especially for those who are health
professionals and policy makers for community safety issues
[12]. Evaluating the content and quality of pharmaceutical dosage
forms is among the integral parts of the quality control (QC) and Good Manufacturing Practices (GMP) [11]. Unfortunately herb shops do not control their herbal formulations and add active pharmaceutical ingredients to hand-made dosage forms to enhance pharmacologic activity and to get more profit out of their business [7]. World Health Organization (WHO) has definitions for substandard, spurious, falsely labeled, falsified and counterfeit (SSFFC) medicinal products. One of these definitions is a product with wrong active pharmaceutical ingredients (APIs) [13]. Recent reports have raised the suspicious of the presence of APIs in herbal drugs advertised for bodybuilding and athletics performance enhancement [4, 14]. There are many formal legal complaints that had been set out the facts and reasons to court outlining the presence of many side effects after the use of herbal drugs. Also we have noticed some adverse drug reactions with several clinical manifestations in cases referred from gym clubs to jurisdiction authorities to be investigated. Forensic medicine practitioners are responsible to evaluate these claims in professional commissions with regard to medical examination and forensic toxicology analysis of suspicious drugs.

Analysis of fake and adulterated herbal supplements is one of the important area of scientific research within the fields of quality control, complementary medicine, forensic and analytical toxicology. There are some reports concerning the forensic toxicology analysis of herbal drugs in Iran [5–7, 15, 16]. But contaminated and adulterated herbal weight gain drugs have seldom been discussed. A few reports with small sample sizes had been performed to detect APIs in bodybuilding herbal drugs in Iran. Jalili et al. (2015), in their study analysed three samples of herbal weight gain drugs and found dexamethasone as adulterant in the samples. Also they found sildenafil and tadalafil in enhancing herbal remedies [16]. Cho et al., confirmed the presence of dexamethasone, cortisone-21-acetate, prednisone-21-acetate and dexamethasone as adulterants in food supplements advertised for the treatment inflammatory diseases [17]. Contamination of dietary supplements with pharmacologic ingredients was verified by Odoardi et al. (2015). In their study methandienone, stanozolol and testosterone were explored as anabolic agents in dietary supplements [18]. As there are few reports about the analysis of fake herbal drugs used as athletics performance enhancer or bodybuilders we designed the present study to identify and quantify active pharmaceutical ingredients in adulterated herbal weight gain drugs. To gain the goal of the study herbal drugs advertised as body builder or weight gain aid were analysed from analytical toxicology point of view.

Materials & methods

Materials and reagents

Acetonitrile, chloroform, methanol (HPLC grade solvents), phosphoric acid, potassium dihydrogen phosphate (KH2PO4), hydrochloric acid, boric acid and sodium hydroxide were purchased from Merck Chemical Co. (Darmstadt, Germany). Buffers, mobile phase for ultra high performance liquid chromatography (UHPLC) system and eluents were prepared with HPLC grade water for chromatography (Merck Millipore). Drug standards for cyproheptadine, dexamethasone and prednisolone were prepared from European Pharmacopoeia, Strasbourg (France) and Sigma Chemical Co. respectively. Helium gas (99.99% purity) was supplied by Roham Co. (Tehran, Iran). Amitriptyline was supplied by Daru Pakhsh Pharmaceutical Chemical Co.

Methods

Method validation procedures

Standards were run on a daily and 3 day basis for assay calibration and integration the areas of peaks by the EZChrom Elite software.

In the present study the most common detected APIs (cyproheptadine and dexamethasone) were evaluated quantitatively in counterfeit herbal drugs. In the present study prednisolone and amitriptyline were adopted as internal standards because their structure, retention time and extraction efficiency are similar to those of dexamethasone and cyproheptadine respectively (Figs. 1 and 2). Linearity, limit of detection (LOD), limit of quantitation (LOQ), accuracy, precision and repeatability of the method were evaluated.

Linearity

When obtained test results of an analysis are proportional to the amount of the desired analyte in experiment medium, the quantitative analysis is linear [15].

Fifty μL of methanolic stock (1 μg/mL) of prednisolone and amitriptyline were used as internal standards for quantitative analysis of dexamethasone and cyproheptadine. The linearity of cyproheptadine was evaluated using seven concentrations of 250, 500, 750, 1000, 2000, 2500 and 3000 ng/mL of cyproheptadine. Each concentration was analysed three times. Regression line was drawn and expressed as correlation coefficient (R2 = 0.9956) using least square method for the assessment of correlation between area under the curve (AUC) and cyproheptadine concentration.
Regression line was drawn for dexamethasone at 500, 750, 1000, 1500, 2000, 3000 and 4000 ng/mL concentrations after triplicate analysis ($R^2 = 0.991$).

**Limit of detection (LOD) and limit of quantitation (LOQ) measurement**

LOD and LOQ of cyproheptadine and dexamethasone were calculated by the proposed method as the concentration with signal/noise = 3 and signal/noise = 10 respectively. For LOD determination, low and decreasing concentrations of cyproheptadine and dexamethasone were spiked in distilled water until signal/noise of about 3 was achieved. LOQ was evaluated in the same manner using ChemStation software.

**Intra and inter-day accuracy, precision and repeatability**

Accuracy indicates that the observed results of an analytical method is compatible with the true concentration of the analyte in the same sample under the same operating conditions and over a short interval of time. Precision and repeatability are suitable indicators of random errors [19]. Inter and intra-day study was carried out for the precision assessment. Three different concentrations of cyproheptadine (500, 1000, 2500 ng/mL) were spiked in distilled water for the preparation of quality control (QC) samples. The same QC samples were prepared for dexamethasone at 750, 2000 and 3000 ng/mL concentrations. Three different drug concentrations were analysed three times on the same day ($n = 9$) at an interval time of 1 h for intra-day study. For inter-day study three drug concentrations were analysed three times on three consecutive days ($n = 27$).

Data are summarized as mean ± SD. To analyse the data statistically, we performed a one-way analysis of variance (ANOVA) for repeated measurements of the same concentration using SPSS software (Chicago, USA).

**Herbal drugs analysis**

**Sample collection procedures**

For scientific sample collection, Tehran, the capital of Iran, was divided into five regions (south, north, east, west and center). Sixty hand-made and factory-made body builder and weight gain herbal drug samples in different pharmaceutical dosage forms (tablets, capsules, powders and syrups) were bought from herb shops over 1 year study period, 1st of March 2017 till 30th February 2018. All of the samples had labels indicating “herbal supplements and natural products” and were advised by sellers to promote muscle mass and increase weight.

**Physical characteristics of pharmaceutical dosage forms**

Tablets, capsules and powders were characterized for some properties such as size, shape, color and odor.
Sample preparation steps

Dispersive liquid liquid microextraction (DLLME) is an efficient sample preparation technique. DLLME is a triple system including an aqueous sample containing analytes and a mixture of extracting and dispersing solvents for the isolation of active pharmaceutical ingredients from biologic and non-biologic matrices [20]. The content of gelatin capsules were emptied. All tablets were grinded to fine powders. Extraction procedure was prevalidated in the laboratory [5–7].

One mg of prepared samples (triturated tablets, powders and capsules content) were mixed with one mL water. Two mL 0.1 M borate buffer (pH = 9.2) was added to the mixture. The pH of the analysis medium was adjusted to pH = 12 due to the alkaline characteristics of most drugs that are important in forensic toxicology analysis. Also extraction procedure was repeated at pH = 2–3 and pH = 8–9 for efficient extraction of drugs with acidic structure and opium alkaloids respectively.

A mixture of 2.5 mL methanol+30 μL chloroform (dispersing + extracting solvents) was pushed rapidly to one mL of prepared samples in borate buffer in a 10 mL conical test tube. The mixture was stirred and ultrasonicated for 5 min followed by centrifugation. Chloroform was collected from the end of conical test tube and evaporated to dryness under gentle stream of nitrogen gas. Residue was dissolved in 30 μL of methanol and prepared to be analysed using gas chromatography/mass spectrometry (GC/MS) and UHPLC instrumentations. We should say that other possible herbal ingredients such as alkaloids, flavonoids and inert substances were not analysed in the present study due to little interest in this study context.

Apparatus and analytical conditions

UHPLC was performed using KNAUER photodiode array (PDA) detector equipped with cooling autosampler (PDA-1, 6 channels). Separation of analytes was performed using a Eurospher II 100–3 C-18 (100 mm × 3 mm) column. Two pumps were operated the system; first with degasser module and the second with mixing chamber. High pressure gradient mode with 10 mL/min and 750 bar maximum pressure was used in both pumps. Autosampler AS-1 with 10 μL loop volume, 15 μL tubing volume and 250 μL syringe volume was used. Tray configuration was 48 vials with tray cooling system. Ezchrom chromatographic software was used. Mobile phase consisted of phosphate buffer (pH = 2.32) and acetonitrile (63:37).

The GC/MS method for the detection of many drugs was prevalidated in our laboratory. GC/MS analysis was carried out on an Agilent model gas chromatograph (Agilent model 7890 A, Agilent technologies, Sdn Bhd, Selanger, Malaysia). The injector was fitted with split/splitless injector and a HP5-MS capillary column (30 m length, 0.25 mm ID, 0.25 μm film thickness, cross-linked 5% methyl phenyl silicon). Mass analyser (MS 5975 C, Agilent Technologies) was operated electron impact (70 eV) in full scan mode (50–550 m/z). The chromatographic conditions were as follows: Helium carrier gas (99.999%) was maintained at a...
constant flow of 1.5 mL/min. Inlet and interface temperatures were set at 250 and 280 °C respectively. Injection volume was equal to one μL in splitless mode. Oven temperature was programmed at 60 °C as initial temperature hold for 1 min.

Temperature program rate was 2 °C/min and final temperature was set at 280 °C holding for 15 min. Qualitative and quantitative determination of drugs were done using NIST, Wiley and MPW 2011 libraries. Sample preparation steps and Instrumental conditions were set as general method for the detection of drugs with acidic and basic structures. Tramadol, sildenafil, acetaminophen and caffeine were detected using developed methods.

Results

Results for method validation

Linearity for cyproheptadine

Linear calibration curve was obtained for cyproheptadine at seven different concentrations with correlation coefficient \( R^2 \) equal to 0.9956 and CV < 10%. Linear regression equation was \( y = 15.675x - 2232 \). Figure 3 shows the calibration curve for the concentration ranges of 250–3000 ng/mL of cyproheptadine.

Linearity for dexamethasone

Linear calibration curve for concentration ranges of 500–4000 ng/mL of dexamethasone was achieved with correlation \( R^2 = 0.991 \) and CV < 10%. Linear equation was \( y = 10.428x + 4822.5 \). Figure 4 shows the calibration curve for the concentration ranges of 500–4000 ng/mL of dexamethasone.

Detection and quantitation limits

Table 1 shows LOD and LOQ for cyproheptadine and dexamethasone using UHPLC instrumentation.

Inter and intra-day accuracy and precision

In both inter and intra-day precision study for cyproheptadine and dexamethasone, % coefficient of variation

\[ Y = 10.428X + 4822.5 \]

\[ R^2 = 0.991 \]
were not more than 25% indicating good precision. Tables 2 and 3 show a summary of intra and inter-day validation parameters for cyproheptadine and dexamethasone respectively.

**Analysis results for herbal supplements**

Herbal supplements were purchased in different dosage forms such as capsules \((n=27)\), powders \((n=23)\), tablets \((n=6)\) and syrups \((n=4)\). Capsules were the most prevalent dosage forms \((38.33\%)\). All drugs smell like herbs. Capsules were made with hard gelatin covers encapsulated with white, beige or green color powders similar to dried different parts of herbs. Powders were packed in plastic or paper bags \((20\ g/bag)\). As tablets broken down, they exuded different colors ranging from yellow to brown. Labels of containers indicated that the product contained herbs such as Ginseng, Ginger, Ziziphus, Alfalfa, Malt, Gentian root, Wheat germ, Barley sprouts and other food supplements \((protein, creatine, vitamins and zinc)\). None of the labels had standard logo indicating identity statement, manufacturer, producers and even license from IFDA. There were some statements on the labels such as: “Natural product for fat face”, “Gain 8-10 kilogram in one month”, “With no adverse effects” and “Maximum strength”.

Table 1  Limit of detection (LOD) and limit of quantitation (LOQ) of cyproheptadine and dexamethasone acquired using UHPLC instrumentation

| Drug name       | Limit of detection (LOD) ng/mL | Limit of quantitation (LOQ) ng/mL |
|-----------------|--------------------------------|----------------------------------|
| Cyproheptadine  | 100                            | 250                              |
| Dexamethasone   | 100                            | 500                              |

Capsules and tablets were the most prevalent dosage forms containing APIs. Qualitative analysis of samples showed that 26 \((43.3\%)\) of all pharmaceutical dosage forms contained at least one active pharmaceutical ingredient. Quantitative analysis of tablets and capsules showed that cyproheptadine content was in the range of 0.2–67 mg/tablet or capsule with mean \pm SD equal to 17.28 \pm 20.7 mg/tablet or capsule. Dexamethasone content of dosage forms was equal to 7.39 \pm 3.2 mg/tablet or capsule in the range of 5.5–10.1 mg/tablet or capsule. Cyproheptadine was the only API detected in 16 samples. Dexamethasone was detected in four samples with cyproheptadine. One pack of unlabeled blue tablets contained dexamethasone. Brand names and active pharmaceutical ingredients detected in some brands are shown in Table 4.

It was evidenced that cyproheptadine, tramadol and sildenafil were detected with each other in two samples (Figs. 5 and 6).

Acetaminophen and caffeine were two APIs detected with cyproheptadine in one powder and one capsule dosage forms. Figure 7 shows “Dragon” tablet that contained cyproheptadine, tramadol and sildenafil.

**Discussion**

Results of the present study showed that method validation parameters exhibited acceptable results for linearity, LOD, LOQ, precision and accuracy for quantitative analysis of cyproheptadine and dexamethasone in herbal drugs. According to the results of the present study about 43% of analysed samples contained at least one active pharmaceutical ingredient.

Detecting and proving adulteration of drugs is one of the important tasks for forensic toxicologists and pharmaceutical

Table 2  Intra and inter-day precision and accuracy of cyproheptadine QC samples using described UHPLC instrumentation

| Theoretical concentration (ng/mL) | Calculated concentration (ng/mL) (mean \pm SD, \(n=3\)) | Precision CV (%) | Accuracy recovery (%) |
|----------------------------------|----------------------------------------------------------|-------------------|-----------------------|
| **Intraday assay**               |                                                          |                   |                       |
| Day 1                           |                                                          |                   |                       |
| 500                             | 483.69 \pm 13.44                                         | 3.98              | 94.65                 |
| 1000                            | 963.17 \pm 174.36                                        | 21.24             | 98.03                 |
| 2500                            | 2779.77 \pm 261.22                                       | 9.9               | 98.81                 |
| Day 2                           |                                                          |                   |                       |
| 500                             | 480.93 \pm 2.59                                          | 0.76              | 95.09                 |
| 1000                            | 902.52 \pm 98.77                                         | 15.91             | 98.97                 |
| 2500                            | 2669.46 \pm 58.54                                        | 2.23              | 97.43                 |
| Day 3                           |                                                          |                   |                       |
| 500                             | 483.38 \pm 6.12                                          | 1.23              | 93.23                 |
| 1000                            | 949.89 \pm 51.09                                         | 6.32              | 97.77                 |
| 2500                            | 2760.4 \pm 54.76                                         | 2.09              | 97.9                  |
| **Interday assay**              |                                                          |                   |                       |
| 500                             | 482.70 \pm 9.12                                          | 0.45              | 99.57                 |
| 1000                            | 938.51 \pm 32.4                                         | 4                 | 97.07                 |
| 2500                            | 2766.84 \pm 40.38                                        | 0.42              | 99.43                 |
Table 3  Intra and inter-day precision and accuracy of dexamethasone QC samples using described UHPLC instrumentation

| Theoretical concentration (ng/mL) | Calculated concentration (ng/mL) (mean ± SD, n = 3) | Precision CV (%) | Accuracy recovery (%) |
|----------------------------------|-----------------------------------------------------|------------------|-----------------------|
| **Intraday assay**               |                                                     |                  |                       |
| Day 1                            |                                                     |                  |                       |
| 750                              | 1053 ± 137.02                                       | 15.04            | 97.87                 |
| 2000                             | 1952.42 ± 75.81                                     | 4.18             | 89.90                 |
| 3000                             | 2258.42 ± 172.55                                    | 8.15             | 95.29                 |
| Day 2                            |                                                     |                  |                       |
| 750                              | 1235.64 ± 139.01                                    | 13.30            | 81.81                 |
| 2000                             | 1909 ± 126.69                                       | 8.78             | 92.14                 |
| 3000                             | 2225.95 ± 150.27                                    | 7.08             | 93.90                 |
| Day 3                            |                                                     |                  |                       |
| 750                              | 1067 ± 72.85                                        | 8.21             | 99.43                 |
| 2000                             | 1538.49 ± 48.36                                     | 3.10             | 85.77                 |
| 3000                             | 2226.24 ± 33.67                                     | 1.61             | 93.84                 |
| **Interday assay**               |                                                     |                  |                       |
| 750                              | 1104.48 ± 63.21                                     | 11.52            | 92.64                 |
| 2000                             | 1800.03 ± 37.05                                     | 13.72            | 98.21                 |
| 3000                             | 2226.24 ± 33.67                                     | 0.86             | 94.34                 |

Table 4  Brand names and active pharmaceutical ingredients detected in adulterated herbal weight gain drugs obtained from herb shops, Tehran, Iran

| Product brand name                  | Dosage form      | Detected active pharmaceutical ingredients | Quantity of drugs in formulations |
|-------------------------------------|------------------|--------------------------------------------|----------------------------------|
| Fat Fast White capsules             | Capsules         | Cyproheptadine                              | 1.8 ± 2.2 mg/capsule             |
| Fat Fast Round creamy tablets       | Tablets          | Cyproheptadine                              | 0.5 ± 1.9 mg/tablet              |
| Exir Powder                         | Powder           | Cyproheptadine                              | 51.9 mg/g                        |
| Exir Blue tablets                   | Blue tablets     | Cyproheptadine, Tramadol, Sildenafil         | 22.8 ± 12.7 mg/tablet            |
| Angel Capsules                      | Capsules         | Cyproheptadine, Tramadol, Sildenafil         | 39.2 ± 24.5 mg/capsule           |
| Dragon Oval dark green tablets      | Tablets          | Cyproheptadine, Tramadol, Sildenafil         | 19.5 ± 6.5 mg/tablet             |
| Royal Powder                        | Powder           | Cyproheptadine                              | 63.3 mg/g                        |
| Aflatoon (Herbal protein) Powder    | Powder           | Cyproheptadine                              | 44.1 mg/g                        |
| Red gelatin capsules in unlabeled box | Capsules       | Cyproheptadine, Acetaminophen, Caffeine     | 41.9 ± 2.7 mg/capsule           |
| Tablets in unlabeled box           | Blue tablets     | Dexamethasone                               | 9.7 ± 2.8 mg/tablet              |
| Tablets in unlabeled box           | White tablets    | Cyproheptadine                              | 67 ± 0.3 mg/tablet               |
| Promed Fat Face                     | White tablets    | Cyproheptadine                              | 21.5 ± 4.7 mg/tablet             |
| V.A.M                              | White tablets    | Cyproheptadine                              | 0.2 ± 0.1 mg/tablet              |
| Full Fat Body                       | Creamy tablets   | Cyproheptadine, Dexamethasone               | CYP: 23.3 ± 9.1 mg/tablet        |
| Gain Up                             | White powder     | Cyproheptadine, Dexamethasone               | DEX: 9.5 ± 4.0 mg/tablet         |
| Bomba                               | White powder     | Cyproheptadine                              | 56.3 mg/g                        |
| Yotam                               | Green powder     | Cyproheptadine                              | 39.7 mg/g                        |
| Miracle                             | Beige powder     | Cyproheptadine                              | 41.4 mg/g                        |
| Power Apple                         | Green capsules   | Cyproheptadine                              | 0.3 mg/g                         |
| Green hexagon tablets in unlabeled box | Green tablets | Cyproheptadine, Dexamethasone               | CYP: 2 ± 0.6 mg/tablet           |
| TIAR                                | Green Powder     | Cyproheptadine                              | DEX: 5 ± 0.8 mg/tablet           |
| FDA G-Fast                          | Tablets          | Cyproheptadine, Dexamethasone               | CYP: 23.8 ± 13.3 mg/tablet       |
| Barley Sprout Powder                | Beige powder     | Cyproheptadine, Acetaminophen, Caffeine     | 60.7 mg/g                        |
| Barley Malt Powder                  | Creamy powder    | Cyproheptadine                              | 49.3 mg/g                        |
| Wheat Germ Powder                   | Yellow powder    | Cyproheptadine                              | 55 mg/g                          |

a CYP Cyproheptadine, b DEX Dexamethasone
analysts [21]. Consistent with the results of the previous studies, the method was well validated for quantitative analysis of cyproheptadine [21, 22]. The difference in obtained LOD and LOQ were attributed to difference in the sample preparation methods and analysis conditions. Maham et al., 2013 validated a method for the qualitative determination of cyproheptadine in urine sample using DLLME-HPLC method [22]. However they had used acetonitrile as dispersing solvent.

The method was validated for quantitative analysis of dexamethasone as undeclared API in weight gain supplements too. LOD and LOQ for dexamethasone were 100 and 500 ng/mL respectively. Friedrich et al., 2009 in their study validated a rapid UV spectrophotometric method for dexamethasone analysis in tablets. They stated that LOD and LOQ for dexamethasone were found to be 0.52 and 1.56 μg/mL respectively [23]. The discrepancy between our results and the results stated by these authors may be due to the use of different techniques in the method validation processes.

The main and second aim of the study was to analyse herbal weight gain drugs used by bodybuilders, athletics and geriatric population to promote muscle and body strength.

Results of the present study demonstrated that herbal weight gain drugs in Tehran, Iran were laced with cyproheptadine, dexamethasone, sildenafil, tramadol, acetaminophen and caffeine. In view of great tendency for herbal drugs all over the world, it is necessary to analyse counterfeit herbal drugs. WHO reported that 80% of patients in developing countries choose herbal drugs as the first-line therapy [24]. This high demand and economic incentives are among the most important factors that encourage herbal drug manufacturers to adulterate drugs [25]. Also the desire to get fast and effective results in combination with widespread availability of food supplements via internet sites encourages people to use these drugs [7]. A potential recurring theme was the APIs found in herbal drugs labeled as natural supplements, tailored to deliver effectiveness and therapeutic outcomes. Some studies highlighted the presence of undeclared APIs in weight gain drugs [4, 16]. Cyproheptadine was the most prevalent adulterant in herbal weight gain drugs in the present study. In line with the results of the present study, cyproheptadine and dexamethasone were the two contaminants in herbal drugs used for the treatment of back pain in previous studies [4].

Many drugs are listed by other scholars as to be obesogenic and promote weight gain as their side effects including cyproheptadine, corticosteroids and many other drug categories [26]. This effect can arise from different drugs mechanisms. Appetite stimulation is one of the side effects of cyproheptadine that cause increase in food intake and weight gain [27]. In accordance with the results of the present study, dexamethasone was the most common contaminant in dietary supplements in Korea advertised for the treatment of bone ache, arthritis and joint pain [17]. Dexamethasone induces weight gain even if low doses used. Sodium retention and edema are among the most common side effects of dexamethasone [28]. Also dexamethasone exerts its obesogenic activity via increasing appetite [26]. That is why these drugs are added deliberately to herbal weight gain drugs.

It was observed that sildenafil, tramadol, caffeine and acetaminophen in some formulations. To the best of our
knowledge and literature review this is the first report of detecting sildenafil and tramadol as adulterant in herbal weight gain drugs. The role of tramadol, acetaminophen and caffeine is obscure for us. One possible explanation for adding sildenafil to herbal drugs is that sildenafil shows viable pharmacologic interventions to increase muscle function [29]. Skeletal muscle function reduces in situations such as aging as well as cancer cachexia and bed rest [29]. Body builders and athletics favor to improve muscle function for racing. Changes in mass and quality of muscle affect skeletal muscle function. Therefore protein synthesis is one of the ways to improve muscle function [29]. Sildenafil causes protein synthesis, alteration in protein expression, nitrosylation and reduction in muscle fatigue via augmentation of nitric oxide-cyclic guanosine monophosphate signaling. Sildenafil improves skeletal muscle oxygenation during exercise in subjects with

Fig. 6 GC/MS chromatograms (a) and mass spectra of cyproheptadine, dexamethasone and tramadol (b, c, d) separated from contaminated herbal weight gain drugs.
intermittent claudication [30]. Another assumption for adding multiple drug classes to natural products is to solve many difficulties such as decreased libido or pain in elderly population. Also it is assumed that tramadol and acetaminophen were added to herbal drugs to relieve pain in elderly patients. Sildenafil can resolve loss of sexual desire in older subjects [31]. It is well recognized that some drugs such as caffeine may be added to herbal supplements as athletics performance enhancer, stimulant or energetics [7].

In some instances, contaminated herbal supplements vary widely in APLs concentrations and contain drugs much greater than prescription strength [32]. Cyproheptadine was detected in higher amounts of therapeutic doses in Traditional Chinese Medicines [29]. In the present study quantitative analysis of dosage forms showed that cyproheptadine and dexamethasone content were higher than therapeutic doses (more than tenfold) and also dosage forms had not content uniformity for active ingredients. The typical dose for cyproheptadine is 2–4 mg and each standard dexamethasone tablet contains 0.5 mg of dexamethasone as active ingredient. The worst scenario is that these dosage forms are prescribed as two or three capsules or tablets/day. However the adverse effects of added pharmacologic ingredients should be considered even they are present in low concentrations in final product [33].

Conclusion

Results of the present study showed that herbal drugs that are advised for weight gain and bodybuilding in Tehran, Iran are not natural whatsoever. They contain active pharmaceutical ingredients in higher doses than therapeutic amounts. Validated method for quantitative analysis of dexamethasone and cyproheptadine proved to be sensitive and had shown enough precision and repeatability. Although synthetic drugs cannot be produced except by permission of the licensing authorities, there is no regulation for the production of herbal drugs. Therefore the quality and safety of natural supplements must be assured for patients’ health.

References

1. Behnood-Rod A, Afzali Poor Khoshkbejari M, Pourzargar P, Hassanzadeh M, Moharamzad Y, Foroughi F. Complementary and alternative medicine use among Iranian patients attending urban outpatient general practices. Complement Ther Clin Pract. 2018;30:58–63.
2. Khazan M, Hedayati M, Askari S, Azizi F. Adulteration of products sold as Chinese herbal medicines for weight loss with thyroid hormones and PCP. J Herb Med. 2013;3:39–43.
3. Domenech-Carbo A, Martini M, de Carvalho LM, Viana C, Domenech-Carbó MT, Silva M. Screening of pharmacologic adulterant classes in herbal formulations using voltammetry of nanoparticles. J Pharm Biomed Anal. 2013;74:194–204.
4. Rocha T, Amaral JS, Oliveira MB. Adulteration of dietary supplements by the illegal addition of synthetic drugs: a review. Compr Rev Food Sci Food Saf. 2016;15(1):43–62.
5. Foroughi MH, Akhgari M, Jokar F, Mousavi Z. Identification of undeclared active pharmaceutical ingredients in counterfeit herbal medicines used as opioid substitution therapy. Aust J Forensic Sci. 2017;49(6):720–9.
6. Hafizi Fard H, Akhgari M. Analytical perspectives of chemical adulterants in herbal sexual enhancer drugs. J Pharm Pharmacogn Res. 2018;6:45–53.
7. Dastjerdi AG, Akhgari M, Kamali A, Mousavi Z. Principal component analysis of synthetic adulterants in herbal supplements advertised as weight loss drugs. Complement Ther Clin Pract. 2018;31:236–41.
8. Brown AC. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series. Food Chem Toxicol. 2017;107(Pt A):449–71.
9. Farzaei MH, Bahramisoltani R, Ghabadi A, Farzaei F, Najafi F. Pharmacological activity of Mentha longifolia and its phytoconstituents. J Tradit Chin Med. 2017;37(5):710–20.
10. Cheraghali AM. Trends in Iran pharmaceutical market. Iran J Pharm Res. 2017;16(1):1–7.
11. Höllein L, Kaale E, Mwalwisi YH, Schulze MH, Holzgrabe U. Routine quality control of medicines in developing countries: analytical challenges, regulatory infrastructures and the prevalence of counterfeit medicines in Tanzania. Trends Anal Chem. 2016;76:60–70.
12. Kamsu-Foguem B, Foguem C. Adverse drug reactions in some African herbal medicine: literature review and stakeholders’ interview. Integ Med Res. 2014;3(3):126–32.
13. WHO. Media Centre. Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products. Fact sheet. 2016. http://www.who.int/mediacentre/factsheets/fs275/en. Accessed 18 Oct 2017.
14. Maughan RJ, Greenhaff PL, Hespel P. Dietary supplements for athletes: emerging trends and recurring themes. J Sports Sci. 2011;29(Suppl):S57–66.
15. Fakhri S, Mohammadi B, Jalili R, Hajialyani M, Bahrami G. Screening and confirmation of different synthetic adulterants in slimming products. Asian J Pharm Clin Res. 2018;11(2):260–4.
16. Cho SH, Park HJ, Lee JH, Kim HJ, Cho S, Yoon CY, et al. Monitoring of 35 illegally added steroid compounds in foods and dietary supplements. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31:1470–5.
17. Odoardi S, Castrignanò E, Martello S, Chiarotti M, Strano-Rossi S. Determination of anabolic agents in dietary supplements by liquid chromatography-high-resolution mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2015;32(5):635–47.

18. Jalili R, Miraghaei S, Mohammadi B, Babaei A, Bahrami G. Detection of corticosteroid compounds and phosphodiesterase inhibitors (PDH-5) as counterfeit in herbal products available in Iranian market by HPLC method. J Rep Pharma Sci. 2015;4(1): 75–81.

19. VBR A, Yusop Z, Jaafar J, Aris AB, Majid ZA, Umar K, et al. Development and validation of a selective, sensitive and stability indicating UPLC–MS/MS method for rapid, simultaneous determination of six process related impurities in darunavir drug substance. J Pharm Biomed Anal. 2016;128:141–8.

20. Sharifi V, Abbasi A, Nosrati A. Application of hollow fiber liquid phase microextraction and dispersive liquid–liquid microextraction techniques in analytical toxicology. J Food Drug Anal. 2016;24(2): 264–76.

21. Görög S. Identification in drug quality control and drug research. Trends Anal Chem. 2015;69:114–22.

22. Maham M, Kiarostami V, Waqif-Husain S, Abroomand-Azar P, Tehrani MS, Sharifabadi MK, et al. Extraction and determination of cyproheptadine in human urine by DLLME-HPLC method. Iran J Pharm Res. 2013;12(2):311–8.

23. Friedrich RB, Ravanello A, Cichota LC, Rolim CM, Beck RC. Validation of a simple and rapid UV spectrophotometric method for dexamethasone assay in tablets. Quim Nova. 2009;32:1052–4.

24. Skalicka-Woźniak K, Georgiev MI, Orhan IE. Adulteration of herbal sexual enhancers and slimmers: the wish for better sexual well-being and perfect body can be risky. Food Chem Toxicol. 2017;108(Pt B):355–64.

25. Yang IC, Tsai CY, Hsieh KW, Yang CW, Ouyang F, Lo YM, et al. Integration of SIMCA and near-infrared spectroscopy for rapid and precise identification of herbal medicines. J Food Drug Anal. 2013;21(3):268–78.

26. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395–404.

27. Lulebo AM, Bavuidibo CD, Mafuta EM, Ndolo JD, Lievin’s Cornelle MM, Kabundji DM, et al. The misuse of Cypriheptadine: a non-communicable disease risk behaviour in Kinshasa population, Democratic Republic of Congo. Subst Abuse Treat Prev Policy. 2016;11:7.

28. Touma Z, Urowitz MB. Systemic Glucocorticoids. In: Tsokos GC, editor. Systemic lupus erythematosus: basic, applied and clinical aspects. 1st ed. Cambridge, Massachusetts, USA: Elsevier, Academic Press; 2015. pp. 521–523.

29. Sheffield-Moore M, Wiktorowicz JE, Soman KV, Danesi CP, Kinsky MP, Dillon EL, et al. Sildenafil increases muscle protein synthesis and reduces muscle fatigue. Clin Transl Sci. 2013;6(6): 463–8.

30. Rosegunini BT, Hirai DM, Alencar MC, Ramos RP, Silva BM, Wolosker N, et al. Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication. Am J Phys Regul Integr Comp Phys. 2014;307(4): R396–404.

31. Sathyarayaraya Rao TS, Tandon A, Manohar S, Mathur S. Clinical practice guidelines for management of sexual disorders in elderly. Indian J Psychiatry. 2018;60(Suppl 3):S397–409.

32. Carvalho LD, Cohen PA, Silva CV, Moreira AP, Falcão TM, Dal Molin TR, et al. A new approach to determining pharmacologic adulteration of herbal weight loss products. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(11):1661–7.

33. Coghlan ML, Maker G, Crighton E, Haile J, Murray DC, White NE, et al. Combined DNA, toxicological and heavy metal analyses provides an auditing toolkit to improve pharmacovigilance of traditional Chinese medicine (TCM). Sci Rep. 2015;5:17475.